Atlas Brown Inc. Increases Stock Position in Pfizer Inc. (NYSE:PFE)

Atlas Brown Inc. boosted its stake in Pfizer Inc. (NYSE:PFE) by 3.8% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 72,917 shares of the biopharmaceutical company’s stock after buying an additional 2,701 shares during the quarter. Atlas Brown Inc.’s holdings in Pfizer were worth $1,934,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also made changes to their positions in PFE. Strategic Financial Concepts LLC acquired a new position in shares of Pfizer in the 2nd quarter valued at about $38,000. Quest Partners LLC bought a new position in Pfizer during the 2nd quarter worth approximately $570,000. Angeles Wealth Management LLC boosted its holdings in Pfizer by 24.0% in the second quarter. Angeles Wealth Management LLC now owns 11,580 shares of the biopharmaceutical company’s stock worth $324,000 after purchasing an additional 2,239 shares during the period. AGF Management Ltd. grew its position in shares of Pfizer by 6.7% during the 2nd quarter. AGF Management Ltd. now owns 1,223,841 shares of the biopharmaceutical company’s stock valued at $34,243,000 after buying an additional 76,464 shares during the last quarter. Finally, HHM Wealth Advisors LLC raised its position in shares of Pfizer by 9.3% during the 2nd quarter. HHM Wealth Advisors LLC now owns 6,311 shares of the biopharmaceutical company’s stock worth $177,000 after purchasing an additional 538 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Down 0.4 %

PFE traded down $0.11 during trading on Friday, reaching $26.75. The company had a trading volume of 24,283,658 shares, compared to its average volume of 33,808,176. The company has a market cap of $151.59 billion, a P/E ratio of 36.15, a PEG ratio of 0.63 and a beta of 0.64. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The business’s fifty day moving average price is $26.21 and its 200 day moving average price is $28.05.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The firm had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. During the same quarter in the previous year, the business posted ($0.17) EPS. The business’s quarterly revenue was up 31.2% compared to the same quarter last year. Equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.43%. The ex-dividend date of this dividend is Friday, January 24th. This is a boost from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio (DPR) is currently 232.43%.

Insider Buying and Selling

In related news, Director Scott Gottlieb purchased 1,000 shares of Pfizer stock in a transaction that occurred on Wednesday, October 30th. The shares were acquired at an average price of $28.24 per share, with a total value of $28,240.00. Following the completion of the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at $282,400. This represents a 11.11 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.06% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on PFE shares. StockNews.com downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Citigroup assumed coverage on shares of Pfizer in a research note on Friday, October 25th. They issued a “neutral” rating and a $30.00 price target for the company. Bank of America reiterated a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a research note on Tuesday, December 10th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research note on Wednesday, October 23rd. Finally, Sanford C. Bernstein initiated coverage on Pfizer in a research note on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.00.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.